The antibody that inhibits CD-52 is known as Alemtuzumab, an IgG1k humanized antibody that binds to the CD-52 cell surface, which is indicated for chronic lymphatic leukaemia. This evidence concerns the gene CD52 and B-cell chronic lymphocytic leukemia.